BRIEF published on 07/24/2024 at 12:35, 4 months 28 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
BRIEF published on 07/24/2024 at 12:35, 4 months 28 days ago Palvella Therapeutics et Pieris Pharmaceuticals annoncent un accord de fusion définitif Financement Nasdaq Biopharmaceutique Fusionnement QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 4 months 28 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 8 months 2 days ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
BRIEF published on 04/19/2024 at 18:15, 8 months 2 days ago Pieris Pharmaceuticals annonce un regroupement d'actions de 1 pour 80 Réglementation Financière Pieris Pharmaceutique Regroupement D'actions Inversé Conformité NASDAQ Ajustement Des Stocks
PRESS RELEASE published on 04/19/2024 at 18:10, 8 months 2 days ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 8 months 25 days ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
BRIEF published on 03/27/2024 at 13:05, 8 months 25 days ago Pieris Pharmaceuticals annonce une nouvelle stratégie pour maximiser le potentiel financier Valeur Pour Les Actionnaires Pieris Pharmaceutique Réorganisation Stratégique Paiements D'étape Potentiel De Redevances
PRESS RELEASE published on 03/27/2024 at 13:00, 8 months 25 days ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 12/21/2024 at 01:30, 17 hours 21 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 21 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 46 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 21 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 6 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 41 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 55 minutes ago CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/21/2024 at 12:17, 6 hours 34 minutes ago AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 6 hours 34 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 17:55, 1 day ago Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024
